Giuseppe
Emeritus
[Source: Antimicrobial Agents and Chemotherapy, full page: (LINK). Abstract, edited.]
Regional Resistance Surveillance Program Results for Twelve Asia-Pacific Nations (2011)
Rodrigo E. Mendes 1, Myrna Mendoza 2, Kirnpal K. Banga Singh 3, Mariana Castanheira 1, Jan M. Bell 4, John D. Turnidge 4, Stephen S.F. Lin 5 and Ronald N. Jones 1*
Author Affiliations: <SUP>1</SUP>JMI Laboratories, North Liberty, Iowa, USA <SUP>2</SUP>Philippines General Hospital, Manila, Philippines <SUP>3</SUP>Universiti Sains Malaysia, Health Campus, Kelantan, Malaysia <SUP>4</SUP>School of Molecular and Biomedical Sciences, University of Adelaide, Adelaide, Australia <SUP>5</SUP>Pfizer Inc., Shanghai, China
ABSTRACT
The Regional Resistance Surveillance program monitored susceptibility rates and developing resistance by geographic region including 12 Asia-Pacific (APAC) countries. Reference broth microdilution methods susceptibility/interpretations were applied, processing 5,053 strains. Among Staphylococcus aureus (37% MRSA, highest in Korea [73%]), linezolid (LZD), tigecycline (TIG) and vancomycin (VAN) were 100% active, but 33 and 34% of strains were levofloxacin (LEV)- or macrolide-resistant, respectively. Streptococcus pneumoniae was most resistant to β-lactams and macrolides (45%); but LZD-, LEV- and TIG-susceptible (>98%). ESBL phenotype rates in Escherichia coli and Klebsiella spp. were 48 and 47%, respectively; highest in Taiwan at 75-91%. Best anti-ESBL phenotype agents were amikacin (81-96% susceptible), colistin (COL; >98%), TIG (>98%) and carbapenems (81-97%). Pseudomonas aeruginosa showed ≥20% resistance to all drugs except COL (99% susceptible). In conclusion, endemic evolving antimicrobial resistances in APAC nations show compromised roles for many commonly used antimicrobials.
FOOTNOTES
* Contact Information: Professor Ronald N. Jones, MD, JMI Laboratories, 345 Beaver Kreek Ctr, Ste A, North Liberty, Iowa, 52317, USA, Phone: 319-665-3370, Fax: 319-665-3371, ronald-jones@jmilabs.com
Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
---------
Regional Resistance Surveillance Program Results for Twelve Asia-Pacific Nations (2011)
Rodrigo E. Mendes 1, Myrna Mendoza 2, Kirnpal K. Banga Singh 3, Mariana Castanheira 1, Jan M. Bell 4, John D. Turnidge 4, Stephen S.F. Lin 5 and Ronald N. Jones 1*
Author Affiliations: <SUP>1</SUP>JMI Laboratories, North Liberty, Iowa, USA <SUP>2</SUP>Philippines General Hospital, Manila, Philippines <SUP>3</SUP>Universiti Sains Malaysia, Health Campus, Kelantan, Malaysia <SUP>4</SUP>School of Molecular and Biomedical Sciences, University of Adelaide, Adelaide, Australia <SUP>5</SUP>Pfizer Inc., Shanghai, China
ABSTRACT
The Regional Resistance Surveillance program monitored susceptibility rates and developing resistance by geographic region including 12 Asia-Pacific (APAC) countries. Reference broth microdilution methods susceptibility/interpretations were applied, processing 5,053 strains. Among Staphylococcus aureus (37% MRSA, highest in Korea [73%]), linezolid (LZD), tigecycline (TIG) and vancomycin (VAN) were 100% active, but 33 and 34% of strains were levofloxacin (LEV)- or macrolide-resistant, respectively. Streptococcus pneumoniae was most resistant to β-lactams and macrolides (45%); but LZD-, LEV- and TIG-susceptible (>98%). ESBL phenotype rates in Escherichia coli and Klebsiella spp. were 48 and 47%, respectively; highest in Taiwan at 75-91%. Best anti-ESBL phenotype agents were amikacin (81-96% susceptible), colistin (COL; >98%), TIG (>98%) and carbapenems (81-97%). Pseudomonas aeruginosa showed ≥20% resistance to all drugs except COL (99% susceptible). In conclusion, endemic evolving antimicrobial resistances in APAC nations show compromised roles for many commonly used antimicrobials.
FOOTNOTES
* Contact Information: Professor Ronald N. Jones, MD, JMI Laboratories, 345 Beaver Kreek Ctr, Ste A, North Liberty, Iowa, 52317, USA, Phone: 319-665-3370, Fax: 319-665-3371, ronald-jones@jmilabs.com
Copyright ? 2013, American Society for Microbiology. All Rights Reserved.
-
---------